Icahn Disses Bristol’s ImClone Bid as Too Cheap

When Bristol-Myers Squibb made its unsolicited $4.5 billion offer for ImClone last week, Bristol CEO James Cornelius sang the praises of financier Carl Icahn, who’s chairman of ImClone’s board, owns nearly 14% of the company’s shares and let’s just say has plenty of power over whether this deal happens. “I have the greatest respect for [...]